Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study

Taiyuan Zhang, Yingying Wu, Zhipeng Cheng, Ao Zhang, Lin Liu, Lu Zhang, Danying Liao, Wei Xie, Fang Liu, Guohui Cui, Yu Hu, Heng Mei, Jun Fang

Blood (2025) 146 (Supplement 1): 7207.

https://doi.org/10.1182/blood-2025-7207

Published: 2025

Journal Articles

Lipo-MIT-based bridging therapy enables effective CAR-T treatment in high-risk relapsed or refractory B-cell lymphoma

Yun Kang, Danying Liao, Wei Xie, Lin Liu, Yinqiang Zhang, Heng Mei

Blood (2025) 146 (Supplement 1): 5935.

https://doi.org/10.1182/blood-2025-5935

Published: 2025

Journal Articles

Inotuzumab ozogamicin vs blinatumomab bridging optimization and second CD19 CAR-T efficacy in Relapsed/Refractory B-ALL

Lin Liu, Danying Liao, Weijiayi Wang, Wei Xie, Jia Xu, Yinqiang Zhang, Fen Zhou, Heng Mei

Blood (2025) 146 (Supplement 1): 2398.

https://doi.org/10.1182/blood-2025-2398

Published: 2025

Journal Articles

Bendamustine combined with fludarabine/cyclophosphamide as a enhanced lymphodepletion regimen demonstrates favorable efficacy and safety in CAR-T therapy for extranodal/bulky R/R B-cell lymphoma

Cong Lu, Danying Liao, Lin Liu, Wei Xie, Yun Kang, Yinqiang Zhang, Heng Mei

Blood (2025) 146 (Supplement 1): 1950.

https://doi.org/10.1182/blood-2025-1950

Published: 2025

Journal Articles

Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine + venetoclax (AZA/VEN) and associated with worse outcomes in AML

Daniel Peters, Diana Abbott, Jingjing Zhang, Jacob Fang, Zenggang Pan, Jeffrey Schowinsky, Jonathan Gutman, Andrew Kent, Mathew Angelos, Christine McMahon, Maria Amaya, Marc Schwartz, Wei Xie, Jonathan Galeotti, Jill Buss, Ann-Kathrin Eisfeld, Curtis Lachowiez, Joshua Zeidner, Daniel Pollyea

Blood (2025) 146 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2025-3377

Published: 2025

Journal Articles

TPO-ras for persistent thrombocytopenia following CAR-T therapy in multiple myeloma: A multicenter clinical experience

Yinqiang Zhang, Zhaozhao Chen, Yingying Li, Wei Xie, Chunrui Li, Heng Mei

Blood (2025) 146 (Supplement 1): 4077.

https://doi.org/10.1182/blood-2025-4077

Published: 2025

Journal Articles

BCMA-targeted CAR T cells for multi-refractory primary immune thrombocytopenia: A pilot study

Jinhui Shu, Min Xu, Wei Xie, Lin Liu, Qiuzhe Wei, Hongjian Li, Jishuai Zhang, Yu Hu, Heng Mei

Blood (2025) 146 (Supplement 1): 1267.

https://doi.org/10.1182/blood-2025-1267

Published: 2025

Journal Articles

Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma

Yinqiang Zhang, Lin Liu, Liman Su, Qiaolin Liu, Wei Xie, Heng Mei

Blood (2025) 146 (Supplement 1): 7261.

https://doi.org/10.1182/blood-2025-7261

Published: 2025

Journal Articles

Mitochondrial mass in pre-lymphodepletion T cells predicts early response to CAR-T therapy in relapsed/refractory non-Hodgkin lymphoma

Li Cai, Yun Kang, Lin Liu, Wei Xie, Mengyi Du, Heng Mei

Blood (2025) 146 (Supplement 1): 4114.

https://doi.org/10.1182/blood-2025-4114

Published: 2025

Journal Articles

Clinical outcomes and novel therapeutic strategies in adult patients with MLL-rearranged acute lymphoblastic leukemia: A monocentric retrospective analysis

Lin Liu, Yinqiang Zhang, Weijiayi Wang, Wei Xie, Mengyi Du, Fen Zhou, Heng Mei

Blood (2025) 146 (Supplement 1): 6890.

https://doi.org/10.1182/blood-2025-6890

Published: 2025

Journal Articles

BTK Inhibitor Synergizes with CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients with Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial

Wenjing Luo, Yinqiang Zhang, Chenggong Li, Jia Xu, Wu Zhuolin, Xindi Wang, Yun Kang, Danying Liao, Haiming Kou, Wei Xie, Wei Xiong, Jun Deng, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 6546.

https://doi.org/10.1182/blood-2024-205304

Published: 2024

Journal Articles

Fratricide-Resistant Anti-CD2 Chimeric Antigen Receptor T-Cells with Endogenous CD2 Knockout Are Highly Effective Against T-Cell Neoplasms

Mathew G. Angelos, Ruchi P. Patel, Yi-Hao Chiang, Wei Xie, Raymone Pajarillo, Carolyn E. Shaw, Ekta Singh, Jason Xu, Avery D. Posey, Alain Rook, Antonia Rotolo, Vinodh Pillai, Stefano A. Pileri, David T. Teachey, Marco Ruella

Blood (2023) 142 (Supplement 1): 885.

https://doi.org/10.1182/blood-2023-181282

Published: 2023

Journal Articles

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

Blood (2023) 142 (Supplement 1): 978.

https://doi.org/10.1182/blood-2023-179527

Published: 2023

Journal Articles

Long-Term Follow-up of Humanized and Murine CD19 CAR-T Cell Therapy for B-Cell Malignancies

Yinqiang Zhang, Mengyi Du, Danying Liao, Wei Xie, Wei Xiong, Heng Mei

Blood (2023) 142 (Supplement 1): 3466.

https://doi.org/10.1182/blood-2023-180440

Published: 2023

Journal Articles

The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms

Peng Li, Sara Brown, Margaret Williams, Thomas White, Wei Xie, Wei Cui, Deniz Peker, Li Lei, Christian A. Kunder, Huan-You Wang, Sarah S. Murray, Jennie Vagher, Tibor Kovacsovics, Jay L. Patel

Blood (2022) 140 (7): 716–755.

https://doi.org/10.1182/blood.2021015135

Published: 2022

Includes: Supplemental data

Journal Articles

CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-136860

Published: 2020

Journal Articles

Neutrophilic leukemoid reaction associated with plasma cell neoplasm mimicking chronic neutrophilic leukemia

Wei Xie, Jie Xu

Blood (2019) 133 (2): 182.

https://doi.org/10.1182/blood-2018-10-881532

Published: 2019

Journal Articles

Multiple Parameter Flow Cytometric Immunophenotyping Is Helpful in the Diagnosis of Patients with Chronic Lymphoproliferative Diseases.

Xuemei Sun, MD, Junhao Chen, BS, Jingyan Xu, MD, Yifen Zhang, MD,PhD, Wei Xie, PhD

Blood (2006) 108 (11): 4632.

https://doi.org/10.1182/blood.V108.11.4632.4632

Published: 2006

Journal Articles

Diagnostic Application of Flow Cytometry in Phosphotyrosine Level Detection and Disease Status Evaluation in Patients with Bcr-abl Positive Leukemia.

Xue-mei Sun, MD, Jun-hao Chen, BS, Lei-lei Chen, BS, Jing-yan Xu, MD, Yong-gong Yang, MD, Wei Xie, PhD

Blood (2006) 108 (11): 4431.

https://doi.org/10.1182/blood.V108.11.4431.4431

Published: 2006

Journal Articles

A Novel Heterozygous Point Mutation Causing Coagulation Factor XII Deficiency as the Molecular Mechanism of Fatal Thrombosis Event in a Chinese Pedigree.

Ying Feng, MD, Ye Xu, MD, Ying Pang, MD, Jing Dai, MD, Wei Xie, MD, Xuhong Zhou, MD, Qiulan Ding, MD, Xuefeng Wang, MD

Blood (2006) 108 (11): 4080.

https://doi.org/10.1182/blood.V108.11.4080.4080

Published: 2006

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study

Lipo-MIT-based bridging therapy enables effective CAR-T treatment in high-risk relapsed or refractory B-cell lymphoma

Inotuzumab ozogamicin vs blinatumomab bridging optimization and second CD19 CAR-T efficacy in Relapsed/Refractory B-ALL

Bendamustine combined with fludarabine/cyclophosphamide as a enhanced lymphodepletion regimen demonstrates favorable efficacy and safety in CAR-T therapy for extranodal/bulky R/R B-cell lymphoma

Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine + venetoclax (AZA/VEN) and associated with worse outcomes in AML

TPO-ras for persistent thrombocytopenia following CAR-T therapy in multiple myeloma: A multicenter clinical experience

BCMA-targeted CAR T cells for multi-refractory primary immune thrombocytopenia: A pilot study

Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma

Mitochondrial mass in pre-lymphodepletion T cells predicts early response to CAR-T therapy in relapsed/refractory non-Hodgkin lymphoma

Clinical outcomes and novel therapeutic strategies in adult patients with MLL-rearranged acute lymphoblastic leukemia: A monocentric retrospective analysis

BTK Inhibitor Synergizes with CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients with Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial

Fratricide-Resistant Anti-CD2 Chimeric Antigen Receptor T-Cells with Endogenous CD2 Knockout Are Highly Effective Against T-Cell Neoplasms

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

Long-Term Follow-up of Humanized and Murine CD19 CAR-T Cell Therapy for B-Cell Malignancies

The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms

CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells

Neutrophilic leukemoid reaction associated with plasma cell neoplasm mimicking chronic neutrophilic leukemia

Multiple Parameter Flow Cytometric Immunophenotyping Is Helpful in the Diagnosis of Patients with Chronic Lymphoproliferative Diseases.

Diagnostic Application of Flow Cytometry in Phosphotyrosine Level Detection and Disease Status Evaluation in Patients with Bcr-abl Positive Leukemia.

A Novel Heterozygous Point Mutation Causing Coagulation Factor XII Deficiency as the Molecular Mechanism of Fatal Thrombosis Event in a Chinese Pedigree.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only